China clarifies standards for post-filed experimental data in Pfizer patent challenge
China's patent regulator has clarified the standards for evaluating post-filed experimental data in pharmaceutical patent challenges, citing a landmark Pfizer drug patent case to explain how such evidence should be assessed...To view the full article, register now.
Already a subscriber? Click here to view full article